A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases
Significant heterogeneity in trial design, populations, and outcome reporting limits the predictive value of placebo-controlled trials. Randomized head-to-head trials remain essential for optimizing IBD therapeutic strategies.
Authors
- Zlata Chkolnaia (ORCID: https://orcid.org/0009-0002-3222-0529)
- M Uzzan
- Laurent Peyrin-Biroulet
Institutions
- Université Paris-Est Créteil (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
- Université de Lorraine (FR)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1093/ecco-jcc/jjag009
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 30.93